UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 132

Sortiert nach

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

Thoracic cancer, 2020-12, Vol.11 (12), p.3482-3489

2020

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

International journal of cancer, 2012-02, Vol.130 (4), p.948-958

2012

Link zum Volltext

Verfügbarkeit prüfen

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

Digestive diseases and sciences, 2011, Vol.56 (1), p.131-138

2011

Link zum Volltext

Verfügbarkeit prüfen

Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20616-e20616

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20002-e20002

2019

Link zum Volltext

Verfügbarkeit prüfen

Should combination chemotherapy be used in all advanced gastric cancer patients?

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16081-e16081

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16008-e16008

2018

Link zum Volltext

Verfügbarkeit prüfen

Is third-line chemotherapy routine practice in recurrent or metastatic gastric cancer?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15558-e15558

2017

Link zum Volltext

Verfügbarkeit prüfen

PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS587-TPS587

2017

Link zum Volltext

Verfügbarkeit prüfen

High expression of Bcl-2 to predict poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving CHOP-based chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e19511-e19511

2015

Link zum Volltext

Verfügbarkeit prüfen

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Acta oncologica, 2015-01, Vol.54 (8), p.1231-1234

2015

Link zum Volltext

Verfügbarkeit prüfen

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

Cancer, 2021-08, Vol.127 (16), p.3019-3028

2021

Link zum Volltext

Verfügbarkeit prüfen

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

European journal of immunology, 2020-11, Vol.50 (11), p.1810-1819

2020

Link zum Volltext

Verfügbarkeit prüfen

Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling

Journal of pineal research, 2015-01, Vol.58 (1), p.50-60

2015

Link zum Volltext

Verfügbarkeit prüfen

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Investigational new drugs, 2020-04, Vol.38 (2), p.360-368

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Journal of clinical oncology, 2019-08, Vol.37 (24), p.2162-2170

2019

Link zum Volltext

Verfügbarkeit prüfen

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

European journal of immunology, 2021-04, Vol.51 (4), p.956-964

2021

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.594-601

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Journal of thoracic oncology, 2022-04, Vol.17 (4), p.558-567

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Oncoimmunology, 2020-01, Vol.9 (1), p.1722023

2020

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Cancer medicine (Malden, MA), 2022-08, Vol.11 (15), p.2944-2956

2022

Link zum Volltext

Verfügbarkeit prüfen

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

Investigational new drugs, 2022-04, Vol.40 (2), p.265-273

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Journal of thoracic oncology, 2023-02, Vol.18 (2), p.223-231

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 132

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(132)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(132)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

Bax Predicts Outcome in Gastric Cancer Patients Treated with 5-fluorouracil, Leucovorin, and Oxaliplatin Palliative Chemotherapy

Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy

Should combination chemotherapy be used in all advanced gastric cancer patients?

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy

Is third-line chemotherapy routine practice in recurrent or metastatic gastric cancer?

Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke

PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer

High expression of Bcl-2 to predict poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving CHOP-based chemotherapy

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke: Clinical and genomic study of nonsmokers with oral tongue cancer

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Melatonin attenuates neutrophil inflammation and mucus secretion in cigarette smoke-induced chronic obstructive pulmonary diseases via the suppression of Erk-Sp1 signaling

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Aktive Filter

Suchergebnisse filtern